News
Yale OBGYN Research Highlighted in ASCO's 14th Annual Report on Progress Against Cancer
Advance of the Year: Progress in Treating Rare Cancers
This year, ASCO names Progress in Treating Rare Cancers as the Advance of the Year. In the United States, rare cancers account for approximately 20% of all cancers diagnosed each year, and incidence rates vary worldwide. Progress has historically lagged behind the achievements made in more common cancers; however, five major studies this past year offer significant steps forward, making this a notable year for advances in rare cancers. Research from the Yale School of Medicine, Department of Obstetrics, Gynecology & Reproductive Sciences was selected as #4: Trastuzumab effective for a rare form of endometrial cancer.
